Market news

Detailed price information for Eyepoint Inc (EYPT-Q) from The Globe and Mail including charting and trades.

WATERTOWN, Mass., Sept. 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employee as inducement award outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 3,00

Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.

WATERTOWN, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that the Company will participate at the following upcoming conferences: Citi 2026 Biopharma Back to School ConferenceForum: Fireside ChatDate: September 9, 2026Time: 8:00 am ETCantor Global Healthcare Conference 2026Forum: Fireside ChatDate: September 10, 2

EyePoint Pharmaceuticals (EYPT) has an average rating of overweight and mean price target of $34.55,

Apellis and Lytenava, mentioned by EyePoint, confirm that it is possible to overcome the failure of one pivotal trial. See why I rate EYPT stock a strong buy.

Eyepoint Pharmaceuticals (EYPT) plunged ~70% after its LUGANO Phase 3 trial for Duravyu in wet AMD failed the primary endpoint due to an anomalous cohort.

EyePoint, Inc. is rated a Sell, citing unfavorable risk/reward and concerns about commercial relevance against standard-of-care. Read more on EYPT stock here.

GlobalData highlighted EyePoint’s Duravyu as a notable drug set to enter the wet AMD market by 2034.

EyePoint's Duravyu misses the phase III wet AMD study's primary goal, sending shares down 67%, but shows lower treatment burden and durable disease control.

RBC Capital said that even if EyePoint’s second Phase 3 study delivers positive results, questions would remain over whether the U.S. Food and Drug Administration would approve the treatment based on a single trial.

EyePoint Pharmaceuticals (EYPT) has an average rating of buy and mean price target of $34.55, accord

Interest in EyePoint (EYPT) has focused on fresh topline data from the Phase 3 LUGANO trial of DURAVYU for wet age related macular degeneration, after the study missed its primary non inferiority endpoint but showed meaningful secondary outcomes. See our latest analysis for EyePoint. The LUGANO update has coincided with a sharp reset in EyePoint's share price. The stock closed at $4.87 after a 1 day share price return that declined 66.98%. This contributed to a year to date share price return...

EyePoint Pharmaceuticals recently reported that its pivotal Phase 3 LUGANO trial of DURAVYU for wet age-related macular degeneration did not achieve the primary non-inferiority endpoint versus aflibercept, while posting clinically meaningful gains in treatment burden reduction and maintaining a favorable safety profile. The company now faces a critical juncture as it pivots investor focus to the upcoming LUCIA Phase 3 readout and a potential US Food and Drug Administration filing in 2027,...

EyePoint Pharmaceuticals said on Monday that its late-stage trial of DURAVYU, an experimental long-lasting eye implant for wet age-related macular degeneration, missed its main goal.

These are some of the stocks posting the largest moves midday.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) reported topline results from LUGANO, the first of two Phase III trials evaluating DURAVYU, a vorolanib intravitreal insert, in patients with wet age-related macular degeneration, or wet AMD. The study did not meet its primary non-inferiority endpoint in the fu

EyePoint (NASDAQ:EYPT) reported that its Phase 3 LUGANO trial of DURAVYU in wet age-related macular degeneration did not achieve its primary endpoint in the full dataset, although the company reported positive secondary outcomes and an ad hoc analysis in which DURAVYU was non-inferior to aflibercept. The Phase 3 LUGANO trial result puts added importance on the second pivotal LUCIA study, due to report topline data in the fourth quarter of 2026, as EyePoint continues to target a potential DURAVYU

EyePoint stock crashed Monday after its eye disease treatment, Duravyu, missed the mark in a final-phase study.

EyePoint posted the results for its Phase 3 Lugano trial, which compared its Duravyu therapy with Aflibercept, the standard treatment for wet AMD.

– DURAVYU was non-inferior to on-label aflibercept control (nominal p-value = 0.0096) in an ad hoc analysis excluding a 4% asymmetric cohort (9 of 211 patients) who experienced vision loss (≥ 15 letters) unrelated to wet AMD; primary endpoint not achieved in full dataset, confounded by this asymmetric cohort – – LUGANO demonstrated clinically meaningful results that reinforce DURAVYU’s potential to improve the treatment paradigm in wet AMD, with compelling key secondary endpoints, including redu

Though its drug missed the key goal of a wet AMD study, EyePoint — as well as analysts — see a path toward approval. Investors may be harder to win over, however.

WATERTOWN, Mass., Aug. 14, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 14,